Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 1, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	94	111	191	199	413	264
Market Cap Growth	-41.93%	-41.93%	-4.09%	-51.84%	56.44%	98.01%
Enterprise Value	49	79	151	134	349	228
Last Close Price	0.41	0.50	1.09	1.17	2.45	1.76
PS Ratio	8.66	11.66	21.32	13.53	95.13	144.57
PB Ratio	1.16	1.44	3.08	2.77	4.54	2.78
P/TBV Ratio	5.23	5.23	30.84	12.45	11.89	6.86
P/FCF Ratio	-	-	307.85	-	-
P/OCF Ratio	-	-	187.79	-	-
EV/Sales Ratio	5.11	8.36	16.88	9.11	80.50	124.70
EV/FCF Ratio	-	-	207.31	-	-
Debt / Equity Ratio	0.03	0.03	0.05	0.05	0.03	0.04
Debt / FCF Ratio	-	-	-	6.03	-	-
Asset Turnover	0.09	0.09	0.08	0.10	0.03	0.02
Quick Ratio	3.47	3.47	2.02	3.07	2.32	5.35
Current Ratio	3.65	3.65	2.14	3.16	2.37	5.66
Return on Equity (ROE)	-26.73%	-26.73%	-32.07%	-32.37%	-46.52%	-20.05%
Return on Assets (ROA)	-12.53%	-12.53%	-11.80%	-9.44%	-21.77%	-14.16%
Return on Capital (ROIC)	-18.58%	-18.58%	-18.82%	-16.61%	-31.93%	-15.35%
Earnings Yield	-19.83%	-16.80%	-11.27%	-13.21%	-10.42%	-7.82%
FCF Yield	-25.21%	-21.36%	-15.33%	0.33%	-5.79%	-7.51%
Buyback Yield / Dilution	-15.94%	-15.94%	-1.69%	-3.22%	-9.64%	-3.10%

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q